Skip to main content
Only direct cytotoxic targets are shown
Gene
Drug Category
Drug Class
Download CSV
Gene NCT ID Antigen/Ligand Binding Type Drug Name Drug NCI Concept Drug Category Drug Class Drug Description Drug Mechanism of Action Target Cytotoxicity Mechanism Disease Disease Type Tissue OncoTree Main Type OncoTree Name Annotation Status
MICA NCT06134960 MICA receptor ligand recognition KD-496 C192807 CAR T Cellular Therapy Autologous, genetically modified CAR T-cell therapy engineered to dual-target NKG2D ligands (e.g., MICA/MICB/ULBP family) and CLDN18.2 on tumor cells, activating T-cell cytotoxicity to treat advanced NKG2DL+/CLDN18.2+ solid tumors. Autologous T cells engineered with a tandem/bispecific CAR that recognizes NKG2D ligands (e.g., MICA, MICB, ULBP family) and CLDN18.2 on tumor cells. Target engagement activates CAR signaling, leading to T-cell cytotoxic killing via perforin/granzyme release and cytokine production, selectively lysing NKG2DL+/CLDN18.2+ cancer cells. Bispecific CAR T cells recognize MICA (an NKG2D ligand) together with CLDN18.2 on the same tumor cell, activating CAR signaling and inducing perforin/granzyme-mediated lysis with cytokine release. Solid Tumor CANCER Other Solid Tumors Solid Tumors ai
MICB NCT06134960 MICB receptor ligand recognition KD-496 C192807 CAR T Cellular Therapy Autologous, genetically modified CAR T-cell therapy engineered to dual-target NKG2D ligands (e.g., MICA/MICB/ULBP family) and CLDN18.2 on tumor cells, activating T-cell cytotoxicity to treat advanced NKG2DL+/CLDN18.2+ solid tumors. Autologous T cells engineered with a tandem/bispecific CAR that recognizes NKG2D ligands (e.g., MICA, MICB, ULBP family) and CLDN18.2 on tumor cells. Target engagement activates CAR signaling, leading to T-cell cytotoxic killing via perforin/granzyme release and cytokine production, selectively lysing NKG2DL+/CLDN18.2+ cancer cells. Bispecific CAR T cells recognize MICB (an NKG2D ligand) together with CLDN18.2 on the same cell, activating CAR signaling and killing via perforin/granzyme-mediated cytotoxicity. Solid Tumor CANCER Other Solid Tumors Solid Tumors ai
ULBP1 NCT06134960 ULBP1 receptor ligand recognition KD-496 C192807 CAR T Cellular Therapy Autologous, genetically modified CAR T-cell therapy engineered to dual-target NKG2D ligands (e.g., MICA/MICB/ULBP family) and CLDN18.2 on tumor cells, activating T-cell cytotoxicity to treat advanced NKG2DL+/CLDN18.2+ solid tumors. Autologous T cells engineered with a tandem/bispecific CAR that recognizes NKG2D ligands (e.g., MICA, MICB, ULBP family) and CLDN18.2 on tumor cells. Target engagement activates CAR signaling, leading to T-cell cytotoxic killing via perforin/granzyme release and cytokine production, selectively lysing NKG2DL+/CLDN18.2+ cancer cells. KD-496 CAR T cells recognize ULBP1 (an NKG2D ligand) together with CLDN18.2 on the same tumor cell, activating CAR signaling and killing the cell via perforin/granzyme-mediated cytolysis and cytokine release. Solid Tumor CANCER Other Solid Tumors Solid Tumors ai
ULBP2 NCT06134960 ULBP2 receptor ligand recognition KD-496 C192807 CAR T Cellular Therapy Autologous, genetically modified CAR T-cell therapy engineered to dual-target NKG2D ligands (e.g., MICA/MICB/ULBP family) and CLDN18.2 on tumor cells, activating T-cell cytotoxicity to treat advanced NKG2DL+/CLDN18.2+ solid tumors. Autologous T cells engineered with a tandem/bispecific CAR that recognizes NKG2D ligands (e.g., MICA, MICB, ULBP family) and CLDN18.2 on tumor cells. Target engagement activates CAR signaling, leading to T-cell cytotoxic killing via perforin/granzyme release and cytokine production, selectively lysing NKG2DL+/CLDN18.2+ cancer cells. KD-496 CAR T cells recognize ULBP2 (an NKG2D ligand) together with CLDN18.2 on the same cell, activating CAR signaling and inducing T-cell cytotoxicity via perforin/granzyme release (and cytokines), killing the dual-positive cells. Solid Tumor CANCER Other Solid Tumors Solid Tumors ai
ULBP3 NCT06134960 ULBP3 receptor ligand recognition KD-496 C192807 CAR T Cellular Therapy Autologous, genetically modified CAR T-cell therapy engineered to dual-target NKG2D ligands (e.g., MICA/MICB/ULBP family) and CLDN18.2 on tumor cells, activating T-cell cytotoxicity to treat advanced NKG2DL+/CLDN18.2+ solid tumors. Autologous T cells engineered with a tandem/bispecific CAR that recognizes NKG2D ligands (e.g., MICA, MICB, ULBP family) and CLDN18.2 on tumor cells. Target engagement activates CAR signaling, leading to T-cell cytotoxic killing via perforin/granzyme release and cytokine production, selectively lysing NKG2DL+/CLDN18.2+ cancer cells. KD-496 CAR T cells recognize ULBP3 (an NKG2D ligand) together with CLDN18.2 on the same tumor cell, activating CAR signaling and killing via perforin/granzyme-mediated cytotoxicity. Solid Tumor CANCER Other Solid Tumors Solid Tumors ai
Displaying 301 - 305 of 3741